Daniel Virgil Thomas Catenacci

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

David Cunningham, Niall C. Tebbutt, André M. Murad et al. · Journal of Clinical Oncology · 2015 · 143 citations

Medicine, Oncology, Pharmacology +12

Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.

Kei Muro, Yung‐Jue Bang, Veena Shankaran et al. · Journal of Clinical Oncology · 2015 · 118 citations

Medicine, Oncology, Pharmacology +17

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

Eunice L. Kwak, Patricia LoRusso, Omid Hamid et al. · Journal of Clinical Oncology · 2015 · 109 citations

Medicine, Oncology, Pharmacology +13

Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.

Yung‐Jue Bang, Hyun-Choel Chung, Veena Shankaran et al. · Journal of Clinical Oncology · 2015 · 45 citations

Medicine, Oncology, Pharmacotherapy +17

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

Daniel Virgil Thomas Catenacci, Nathan Bahary, Sreenivasa Nattam et al. · Journal of Clinical Oncology · 2013 · 39 citations

Medicine, Oncology, Pharmacology +15